Skip to content
stoqly

Integer

ITGR NYSE Health Care Equipment Financials FY2016–FY2025

Integer's revenue rose 8.0% to $1.9 billion in fiscal 2025. Its operating margin was 11.9%, down from 12.1% a year earlier. Free cash flow was $105 million, up 5.3%. It paid out $50 million in dividends and buybacks, 48% of free cash flow. The diluted share count fell 0.1%.

Last close · Oct 23, 2026

$126.54

0.0%
Value it Compare
Revenue Total sales reported in the income statement.
$1.9B
8.0% vs prior year
Operating margin Operating income as a share of revenue.
11.9%
0.2 pts
Net income Profit after all expenses, interest and tax.
$103M
14.3%
Free cash flow Cash from operations minus capital spending.
$105M
5.3%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
6.6%
0.2 pts
Market cap Last close times the latest diluted share count, so it is approximate.
$4.3B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
34.7x
On $3.65 EPS (TTM)

What Integer does

No business description yet.

Legal name
INTEGER HOLDINGS CORPORATION
Fiscal year ends
December 31, 2025
Latest annual report
—
Accession · CIK
0001114483-26-000003
0001114483

Revenue and margins

Integer had $1.9B of revenue in fiscal 2025, up 8.0% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

From fiscal 2016 to 2025, diluted EPS grew 35.3% a year. Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $105M in fiscal 2025, 5.7% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Integer returned $50.0M to shareholders in fiscal 2025, 48% of free cash flow. The diluted share count fell 0.2%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value Integer yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of −$1.2B and divides by 35.6M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Earnings multiple

Value per share

—

Reference multiples: today 34.7x · peers 70.1x · sector 27.9x.

Balance sheet

Cash, debt and the ratios that show how comfortably Integer can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $17.9M$24.3M$23.7M$46.5M$17.2M
Debt incl. finance leases $836M$934M$972M$1.0B$1.2B
Net debt / EBITDA 3.8x4.5x3.6x3.0x3.4x
Debt / equity 0.6x0.7x0.6x0.6x0.7x
Interest coverage 4.3x2.9x3.1x3.7x5.1x
Current ratio 2.8x2.5x2.8x3.0x3.3x
Quick ratio 1.9x1.6x1.8x1.9x2.2x
Total assets $2.6B$2.8B$2.9B$3.1B$3.4B
Total liabilities $1.2B$1.4B$1.4B$1.5B$1.7B
Shareholders' equity $1.4B$1.4B$1.5B$1.6B$1.7B
Net debt (− = net cash) $818M$910M$949M$972M$1.2B

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.5M

4 insiders

Sold, 12 months

$5.3M

3 insiders

Of sales under plans

0%

$0.0M

DateInsiderTradeSharesPriceValueFiling
Sep 15, 2026 Kirk K ThorChief Human Resources Officer Sold 11,767 $126.23 $1.5M Form 4
Sep 14, 2026 Kirk K ThorChief Human Resources Officer Sold 19,773 $126.25 $2.5M Form 4
Sep 8, 2026 Andrew SennPresident, Growth & Innovation Sold 9,408 $126.30 $1.2M Form 4
Mar 13, 2026 Tommy P ThomasVP, Corporate Controller Sold 825 $85.00 $0.1M Form 4
Nov 12, 2025 John A HarrisEVP, Global Ops and Manufactur Bought 1,650 $70.00 $0.1M Form 4
Nov 11, 2025 Tommy P ThomasVP, Corporate Controller Sold 884 $70.15 $0.1M Form 4
Nov 7, 2025 Diron SmithEVP, Chief Financial Officer Bought 1,116 $67.19 $0.1M Form 4
Nov 6, 2025 Cheryl C CappsDirector Bought 1,600 $66.70 $0.1M Form 4
Oct 30, 2025 Payman KhalesPresident & CEO, Director Bought 3,127 $64.94 $0.2M Form 4

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY23FY24FY25
Net income is positive ✓ ✓ ✓
Cash from operations is positive ✓ ✓ ✓
Return on assets rose ✓ ✓ ✕
Cash from operations exceeds net income ✓ ✓ ✓
Debt fell relative to assets ✓ ✓ ✕
Current ratio rose ✓ ✓ ✓
Share count didn't rise ✕ ✕ ✓
Gross margin rose ✓ ✓ ✓
Revenue rose relative to assets ✓ ✓ ✓
F-score 8 / 98 / 97 / 9
Accruals ratio −3.1%−2.8%−2.9%
Altman Z'' 3.233.513.52

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Integer ITGR $4.3B 8.0% 11.9% 5.7% 6.6% 34.7x 7
Integra Lifesciences IART $936M 1.5% −30.2% −1.9% −22.0% 70.1x 5 Compare →
Enovis ENOV $1.2B 6.7% −50.0% 0.9% −26.9% — 4 Compare →
Penumbra PEN $12.8B 17.5% 13.5% 12.5% 18.8% 79.7x 7 Compare →
LivaNova LIVN $4.6B 10.7% 14.4% 12.5% 12.8% 23.9x 5 Compare →

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $1.1B $1.1B $1.2B $1.3B $1.1B $1.2B $1.3B $1.6B $1.7B $1.9B
Gross profit $338M $354M $363M $355M $286M $337M $346M $410M $459M $500M
Research and development $47.9M $48.8M $48.6M $46.5M $48.5M $52.0M $59.8M $62.0M $53.4M $49.5M
Operating income $92.9M $126M $156M $158M $121M $136M $113M $163M $208M $221M
Interest expense $68.3M $64.0M $99.3M $52.5M $38.2M $31.6M $38.6M $53.4M $56.4M $43.2M
Pretax income $28.2M $49.3M $61.1M $105M $86.2M $101M $68.7M $105M $148M $125M
Income tax $3.3M −$37.8M $14.1M $14.0M $8.9M $8.0M $8.9M $16.2M $26.5M $22.6M
Net income $6.0M $66.7M $168M $96.3M $77.3M $96.8M $66.4M $90.6M $120M $103M
Diluted EPS $0.19 $2.08 $5.15 $2.92 $2.33 $2.91 $1.99 $2.69 $3.36 $2.89
Diluted shares 0.03B 0.03B 0.03B 0.03B 0.03B 0.03B 0.03B 0.03B 0.04B 0.04B
Cash flow
Cash from operations $106M $149M $167M $165M $181M $157M $116M $180M $205M $196M
Capital expenditure $58.6M $47.3M $44.9M $48.2M $46.8M $53.5M $74.7M $120M $105M $91.0M
Free cash flow $46.9M $102M $122M $117M $135M $103M $41.7M $60.3M $99.9M $105M
Depreciation and amortization $90.5M $103M $89.0M $77.9M $79.3M $81.4M $92.0M $98.8M $111M $131M
Stock-based compensation $8.4M $14.7M $10.5M $9.3M $9.2M $16.2M $21.0M $23.3M $24.8M $23.2M
Acquisitions $0.0M $0.0M $0.0M $15.0M $5.2M $218M $127M $43.6M $139M $179M
Share buybacks $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $50.0M
Dividends paid $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Dividends and buybacks $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $50.0M
Balance sheet
Cash and short-term investments $52.1M $44.1M $25.6M $13.5M $49.2M $17.9M $24.3M $23.7M $46.5M $17.2M
Total debt $1.7B $1.6B $926M $815M $731M $828M $925M $960M $990M $1.2B
Finance lease liabilities $0.0M $0.0M $0.0M $0.0M $0.0M $8.1M $9.1M $12.3M $28.3M $36.4M
Current assets $517M $532M $416M $415M $413M $453M $558M $618M $671M $770M
Current liabilities $185M $209M $165M $179M $156M $160M $224M $221M $227M $232M
Inventory $225M $177M $190M $167M $149M $156M $209M $229M $247M $254M
Property and equipment, net $372M $235M $231M $246M $254M $277M $317M $393M $466M $536M
Total assets $2.8B $2.8B $2.3B $2.4B $2.4B $2.6B $2.8B $2.9B $3.1B $3.4B
Total liabilities $2.1B $2.0B $1.3B $1.2B $1.1B $1.2B $1.4B $1.4B $1.5B $1.7B
Shareholders' equity $725M $893M $1.1B $1.2B $1.3B $1.4B $1.4B $1.5B $1.6B $1.7B
Margins
Gross margin 31.4% 31.2% 29.9% 28.2% 26.6% 27.6% 26.0% 26.4% 26.7% 27.0%
Operating margin 8.6% 11.1% 12.8% 12.5% 11.2% 11.1% 8.5% 10.5% 12.1% 11.9%
EBITDA margin 17.1% 20.1% 20.1% 18.7% 18.6% 17.8% 15.4% 16.9% 18.6% 19.0%
Net margin 0.6% 5.9% 13.8% 7.7% 7.2% 7.9% 5.0% 5.8% 7.0% 5.6%
FCF margin 4.4% 9.0% 10.1% 9.3% 12.5% 8.5% 3.1% 3.9% 5.8% 5.7%
Returns
Return on capital 3.4% 5.2% 5.4% 7.0% 5.5% 6.1% 4.4% 5.8% 6.8% 6.6%
Return on capital employed 3.4% 4.8% 6.5% 7.3% 5.5% 5.9% 4.5% 6.2% 7.5% 7.3%
Return on equity 0.8% 8.2% 17.2% 8.7% 6.4% 7.4% 4.8% 6.2% 7.6% 6.1%
Return on assets 0.2% 2.4% 6.5% 4.1% 3.3% 3.9% 2.5% 3.2% 4.0% 3.2%
Growth
Revenue growth 34.4% 5.6% 7.0% 3.6% −14.7% 13.8% 9.0% 16.9% 10.4% 8.0%
Net income growth — 1,018.6% 151.9% −42.6% −19.8% 25.3% −31.4% 36.6% 32.3% −14.3%
EPS growth — 994.7% 147.6% −43.3% −20.2% 24.9% −31.6% 35.2% 24.9% −14.0%
FCF growth — 117.6% 19.9% −4.3% 14.8% −23.3% −59.6% 44.7% 65.7% 5.3%
Share count change 17.5% 3.5% 1.7% 1.4% 0.2% 0.4% 0.3% 1.2% 5.6% −0.2%
Financial health
Net debt / EBITDA 9.2x 6.9x 3.7x 3.4x 3.4x 3.8x 4.5x 3.6x 3.0x 3.4x
Debt / equity 2.4x 1.8x 0.9x 0.7x 0.6x 0.6x 0.7x 0.6x 0.6x 0.7x
Interest coverage 1.4x 2.0x 1.6x 3.0x 3.2x 4.3x 2.9x 3.1x 3.7x 5.1x
Current ratio 2.8x 2.5x 2.5x 2.3x 2.6x 2.8x 2.5x 2.8x 3.0x 3.3x
Quick ratio 1.6x 1.7x 1.4x 1.4x 1.7x 1.9x 1.6x 1.8x 1.9x 2.2x
Capital allocation
Capex / revenue 5.5% 4.2% 3.7% 3.8% 4.4% 4.4% 5.6% 7.7% 6.1% 4.9%
Stock comp / revenue 0.8% 1.3% 0.9% 0.7% 0.9% 1.3% 1.6% 1.5% 1.4% 1.3%
Payouts / FCF 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 47.6%
Quality scores
Piotroski F-score 7.0 6.0 5.0 5.0 5.0 7.0 4.0 8.0 8.0 7.0
Altman Z'' 1.5 1.7 2.5 2.7 3.0 3.0 2.9 3.2 3.5 3.5
Accruals ratio −3.4% −2.9% 0.0% −3.0% −4.4% −2.4% −1.9% −3.1% −2.8% −2.9%

Source: SEC EDGAR XBRL filings (CIK 0001114483). Data updated October 22, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open